Omada Health vs Viemed Healthcare
OMDA and VMD side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How OMDA and VMD compare
Omada Health is the larger company, worth 2.7 times as much as Viemed Healthcare ($933M against $348M).
Omada Health grew revenue faster over the last twelve months (43.3% versus 21.8% for Viemed Healthcare).
Viemed Healthcare keeps more of each dollar of sales as profit, with a net margin of 5.0% compared with 4.2% at Omada Health.
Viemed Healthcare scores higher on the StockData Score (18 against 13 for Omada Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | OMDA | VMD |
|---|---|---|
| Size and price | ||
| Market cap | $933M | $348M |
| Share price | $15.24 | $9.13 |
| Change, 1 year | −26.2% | 42.9% |
| Change, 5 years | – | 67.5% |
| Beta (5Y) | 2.38 | 0.58 |
| Employees | 916 | 1,382 |
| StockData Score | ||
| Total score | 13 | 18 (better) |
| Valuation score | 1 | 5 (better) |
| Growth score | 3 | 5 (better) |
| Performance score | 3 | 3 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 24.0× |
| P/S | 2.8× | 1.1× (better) |
| P/B | 3.4× | 2.3× (better) |
| EV/EBITDA | 52.7× | 8.6× (better) |
| P/FCF | 33.1× | 16.3× (better) |
| PEG | – | 0.75 |
| FCF yield | 3.0% | 6.1% (better) |
| Fair value | $9.26 | $11.59 |
| Margin of safety | −64.5% | 21.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 43.3% (better) | 21.8% |
| Revenue growth, 5Y average | – | 15.5% |
| Net income growth (TTM) | – | 14.8% |
| EPS growth (TTM) | – | 15.2% |
| EPS growth, 5Y average | – | −13.9% |
| Profitability | ||
| Gross margin | 70.7% (better) | 57.4% |
| Operating margin | 2.1% | 7.8% (better) |
| Net margin | 4.2% | 5.0% (better) |
| FCF margin | 8.5% (better) | 6.9% |
| Return on equity | 5.7% | 11.0% (better) |
| Return on invested capital | 28.2% (better) | 11.8% |
| Financial health | ||
| Debt / equity | 0.00 | 0.03 (better) |
| Net debt / EBITDA | – | −0.12 |
| Interest coverage | 22.4× | – |
| Current ratio | 4.18 (better) | 1.25 |
| Altman Z-score | 7.47 (better) | 6.46 |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | – | 2.2% |
| Shareholder yield | 0.00% | 2.2% (better) |
| Ownership | ||
| Held by institutions | 85.9% | 71.3% |
| Held by insiders | 5.4% | 15.4% |
| Insider net buying, 12 months | −$14.6M | −$1.6M (better) |
| Short interest, % of float | 15.8% | 4.7% |
Go deeper
- OMDA stock overview
- OMDA income statement
- OMDA valuation and score
- VMD stock overview
- VMD income statement
- VMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.